Hepatocyte growth factor gene therapy

Drug Profile

Hepatocyte growth factor gene therapy

Latest Information Update: 20 Jul 2006

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Gene therapies; Growth factors; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Hepatocyte growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cerebral ischaemia; Liver cirrhosis

Most Recent Events

  • 20 Jul 2006 No development reported - Preclinical for Cerebral ischaemia in Japan (unspecified route)
  • 18 Sep 2002 Preclinical trials in Cerebral ischaemia in Japan (unspecified route)
  • 18 Sep 2002 A preclinical study has been added to the Neurological Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top